Metoclopramide Orifarm

Metoclopramide, the active ingredient in Metoclopramide Orifarm, is a dopamine D2 receptor antagonist presented as an oral tablet for oral use. It is employed to alleviate nausea and vomiting, improve gastric emptying in gastroparesis, and manage symptoms of gastro‑oesophageal reflux disease in adult patients.

GNH USA supplies Metoclopramide Orifarm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable global distribution.

Metoclopramide is indicated for conditions affecting the gastrointestinal tract and the central emetic pathways.

- Nausea and vomiting: reduces episodes by blocking dopamine receptors in the chemoreceptor trigger zone. - Gastroparesis: enhances gastric motility and accelerates stomach emptying. - Gastro‑oesophageal reflux disease: decreases reflux episodes by improving lower esophageal sphincter tone and gastric clearance. - Chemotherapy‑induced nausea: helps control nausea associated with cytotoxic therapy.

Metoclopramide may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Drowsiness - Fatigue - Restlessness - Diarrhea - Dry mouth - Headache

Serious or Rare Side Effects: - Extrapyramidal reactions (e.g., dystonia, akathisia) - Tardive dyskinesia - Neuroleptic malignant syndrome - Depression or suicidal thoughts - Seizures - Anaphylactic or severe allergic reactions

When prescribing Metoclopramide, clinicians should consider several safety measures.

- Assess renal function: dose adjustment may be required in renal impairment. - Monitor for extrapyramidal symptoms: watch for restlessness, muscle rigidity, or tremor. - Avoid in patients with known hypersensitivity to metoclopramide. - Use caution in elderly: increased risk of sedation and falls. - Limit duration of therapy: restrict use to ≤12 weeks to reduce risk of tardive dyskinesia. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Metoclopramide can interact with several drug classes, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Antipsychotics (e.g., haloperidol): additive central nervous system depression. - CYP2D6 inhibitors (e.g., fluoxetine): increased plasma concentrations of metoclopramide. - Anticholinergic agents: reduced pro‑kinetic efficacy.

Moderate Interactions (Monitor Closely): - Opioids: enhanced risk of sedation and respiratory depression. - Alcohol: increased drowsiness and dizziness. - Other dopamine antagonists: additive risk of extrapyramidal effects.